Market Access Strategies for the Global Healthcare Environment mktxs linkedin 1-908-864-4090

Current and Future Payer Landscape Assessment of Metastatic Breast Cancer (MBC) in US and EU-4: Drivers of Willingness to Pay

Challenges

An oncology-focused manufacturer wanted to identify the country-specific drivers of a high willingness to pay for metastatic breast cancer therapies

  • Determination of the primary and secondary endpoints needed to drive willingness to pay
  • Economic/pharmacoeconomic evidence needed by Payers to understand value
  • Role of PROs/QoL in price and access decisions for metastatic cancer treatment

Current and Future Payer Landscape Assessment of Metastatic Breast Cancer in US and EU-4: HTA Analogues

Challenges

An oncology-focused manufacturer wanted to explore the current health technology assessment (HTA) environment in Europe for metastatic breast cancer therapies:

  • Efficacy endpoints needed for evaluation, separated by relevant sub-populations
  • Pharmacoeconomic evidence requirements
  • Impact of patient selection/biomarker on evidence needs
  • Safety concerns and role of QoL

Training LatAm affiliates in Payer negotiation strategies to optimize access of a high priced orphan drug

Challenges

A global drug manufacturer launched an orphan drug in the US and core EU markets, but faced several challenges in access within the LatAm markets that included:

  • Objections to product price
  • Highly misdiagnosed disease, resulting in an unclear target patient profile eligible for treatment
  • Lack of a centralized healthcare system, creating barriers to monitoring product performance